Combination Agents for Multiple Myeloma: Comparative Clinical Effectiveness


( Last Updated : March 18, 2019)
Project Line:
Reference List
Project Sub Line:
Summary of Abstracts
Project Number:
RB1317-000

Details


Question


  1. What is the comparative clinical effectiveness cyclophosphamide + bortezomib + dexamethasone (CyBorD) versus bortezomib + melphalan + prednisone (VMP) for newly diagnosed patients with multiple myeloma where there is no intent for stem cell transplantation?

  2. What is the comparative clinical effectiveness cyclophosphamide + bortezomib + dexamethasone (CyBorD) versus lenalidomide + dexamethasone (RD) for newly diagnosed patients with multiple myeloma where there is no intent for stem cell transplantation?


Key Message

One non-randomized study was indentified regarding the comparative clinical effectiveness of CyBorD versus VMP in newly diagnosed patients with multiple myeloma with no eligiblity for stem cell transplantation.Additionally, no relevant health technology assessments, systematic reviews, meta-analyses and randomized controlled trials were identified regarding the comparative clinical effectiveness of CyBorD to VMP or RD.